Johns Hopkins scientists will go to work studying Bristol-Myers Squibb’s Opdivo and Yervoy, looking for their weak points as the company looks to improve on these blockbuster drugs. They’ll be studying patient tumor samples in four primary research areas: characterization of tumor antigens and tumor antigen-specific T-cells, multifaceted profiling of the tumor microenvironment, assessment of microbiome components that modulate systemic anti-tumor immunity, and elucidation of novel tumor and immuno-metabolism factors that modify responsiveness to immunotherapy.
Genentech is partnering with Halozyme $HALO on a slate of new studies combining Roche’s Tecentriq with the biotech’s PEGPH20. They’re splitting responsibilities for the first two trials, starting with a Genentech-led Phase Ib/II covering six tumor types.
Over the past year Valeant has become the poster child for drug pricing abuses. Its stock price has been eviscerated. Its business model has been abused and subjected to scornful derision. What to do now? Maybe a name change would help, suggests a board member and big investor.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 30,600+ biopharma pros who read Endpoints News by email every day.Free Subscription